Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$121.23 USD
+0.25 (0.21%)
Updated May 16, 2024 03:59 PM ET
After-Market: $121.13 -0.10 (-0.08%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$121.23 USD
+0.25 (0.21%)
Updated May 16, 2024 03:59 PM ET
After-Market: $121.13 -0.10 (-0.08%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Zacks News
Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.
MedTech Industry Stock Outlook - Dec. 2015
by Zacks Equity Research
While the global economy has been on a rollercoaster ride over the past quarter, the MedTech sector has not only held its own, but maintained a stable uptrend.
MedTech Industry Stock Outlook - Dec. 2015
by Zacks Equity Research
While the global economy has been on a rollercoaster ride over the past quarter, the MedTech sector has not only held its own, but maintained a stable uptrend.
3 MedTech Stocks Poised to Trump Earnings in Q3
by Zacks Equity Research
Positive demographic trends, new product cycles, expansion into emerging markets and widespread consolidation are the key traits for the MedTech sector.
MedTech Industry Stock Outlook - July/Aug 2015
by Zacks Equity Research
Recently released government data showed that about 16.4 million uninsured people have gained health insurance coverage since the enactment of the Affordable Care Act five years back.
MedTech Industry Stock Outlook - July/Aug 2015
by Zacks Equity Research
Recently released government data showed that about 16.4 million uninsured people have gained health insurance coverage since the enactment of the Affordable Care Act five years back.
MedTech M&As Continue Regardless of Tax Scenarios
by Zacks Equity Research
MedTech stalwarts are not expected to shy away from hostile acquisition bids this year.